A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
I8G-MC-LMDA - ClinicalTrials.gov - NCT02754830
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.
Trial Summary
Age Range
≥30 yearsConditions the trial is for
Alzheimer's DiseaseWhat the trial is testing?
LY3303560Could I receive a Placebo?
YesEnrollment Goal
72Trial Dates
Apr 25, 2016 - Jul 10, 2018How long will I be in the trial?
Your participation could last up to 16 weeks and include 11 visits to the study center, including a 4 day clinical research unit (CRU) stay.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo